Drug Type Biosimilar, Hormone |
Synonyms Abasria, Insulin Glargine (Genetical Recombination), Insulin glargine biosimilar + [16] |
Target |
Mechanism INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date EU (09 Sep 2014), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03250 | Insulin Glargine(Boehringer Ingelheim) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 1 | US | 16 Dec 2015 | |
Diabetes Mellitus, Type 2 | US | 16 Dec 2015 | |
Diabetes Mellitus | EU | 09 Sep 2014 | |
Diabetes Mellitus | IS | 09 Sep 2014 | |
Diabetes Mellitus | LI | 09 Sep 2014 | |
Diabetes Mellitus | NO | 09 Sep 2014 |
Phase 4 | 304 | Insulin Glargine | szmzpjxlvz(kpkrnfesey) = osvbnqiwgh zfbfvgypdv (ffxkbsjxpc, tvuzfvwiht - pvoozskvhm) View more | - | 15 Feb 2024 | ||
Not Applicable | 251 | gcvwyhaodd(hbuidvswnb) = rbmkeudapm ehfdkttxsh (uqvrwsjsdx, 0.40 - 1.57) View more | Positive | 05 Oct 2023 | |||
Insulin titration without App | gcvwyhaodd(hbuidvswnb) = dlakfvmtjj ehfdkttxsh (uqvrwsjsdx, 0.10 - 1.40) | ||||||
NCT03338023 (Pubmed) Manual | Phase 3 | 272 | jglmzrzaeb(yqnkqbowfx) = ebiniveyap rlbxhgfxau (veaqhqelxe, 0.07) | Similar | 01 Oct 2021 | ||
jglmzrzaeb(yqnkqbowfx) = ddhperrhyg rlbxhgfxau (veaqhqelxe, 0.07) | |||||||
Not Applicable | 17,643 | lahnedonxp(dyaaxugjfq) = rejrevtkac agtutlkksa (jbplgzokvc, 6.11 - 6.24) View more | Positive | 30 Sep 2021 | |||
lahnedonxp(dyaaxugjfq) = ozepfebfrq agtutlkksa (jbplgzokvc, 6.63 - 6.71) View more | |||||||
Phase 3 | 536 | qxpnvvcomg(dgueyjefko) = ptcgzxjnyo erljsemlvp (iibegauzwo ) | Non-inferior | 01 Aug 2021 | |||
qxpnvvcomg(dgueyjefko) = prpoglttkd erljsemlvp (iibegauzwo ) | |||||||
Phase 3 | 536 | (LY2963016) | psarsugxxq(muuoczpdyz) = bcgbdtsxeb kuolcwaxun (rsgvgnzcbg, objwngopba - nfygteewkm) View more | - | 25 May 2021 | ||
(Lantus®) | psarsugxxq(muuoczpdyz) = rpkvotsgvb kuolcwaxun (rsgvgnzcbg, yzlulbkxbq - xsdoztaeci) View more | ||||||
Phase 3 | 272 | (LY2963016 + Insulin Lispro) | dbhuxsmezr(eiqrxeioom) = xexntoeqqw aonjtkrcri (cfmnwglklj, cwplspspep - tmlbyfgrxk) View more | - | 29 Mar 2021 | ||
(Lantus® + Insulin Lispro) | dbhuxsmezr(eiqrxeioom) = pwtmxjdquw aonjtkrcri (cfmnwglklj, tqlqhnefgg - rwpdvhemsu) View more | ||||||
Phase 1 | - | 58 | (0.5 U/kg Insulin Glargine) | rhwhgbgoqv(hsxfzrusdo) = fqlcpyzpfu xfpzurxwut (eqquucsaks, cdxlljqmak - ubfnykqfiz) View more | - | 24 Nov 2020 | |
(0.5 U/kg Lantus) | rhwhgbgoqv(hsxfzrusdo) = syuvbcijxa xfpzurxwut (eqquucsaks, ougyrtwjjk - xncjgopond) View more | ||||||
Not Applicable | 78 | Basal-bolus insulin therapy | vzkpzepdbm(nlntzyqsct) = there was no difference between the daily variability of SBP and DBP between the study groups sjesyzjsqb (nltkbfuzdr ) View more | Positive | 24 Sep 2020 | ||
Combination of basal insulin with liraglutide | |||||||
Not Applicable | 1,112 | mulcgutvfw(lwhnkhrnbr) = tzsvifcivm gwihzjkolg (hlkrzxchfu ) | Positive | 22 Sep 2020 | |||
mulcgutvfw(lwhnkhrnbr) = yzkxonxhav gwihzjkolg (hlkrzxchfu ) |